Century Therapeutics (IPSC) Piper Sandler 37th Annual Healthcare Conference summary

Key program updates and pipeline progress

• Advancing iPSC-derived cell therapies, including CAR T, CAR NK, and beta islet cells for autoimmune diseases, cancer, and type 1 diabetes.

• Beta islet cell program (CNTY813) aims to treat type 1 diabetes with reduced or no chronic immunosuppression, targeting IND-enabling studies by year-end and IND submission as early as next year.

• CD19 CAR-iT (CNTY-308) is set to enter clinical trials next year, focusing initially on autoimmune diseases with potential for reduced or no lymphodepletion.

• Phase 1 Carmel study of CD19 CAR-NK (CNTY-101) in multiple autoimmune diseases is ongoing, with initial safety and translational data expected at an upcoming conference.

• Discontinued Calypso study to focus resources on more promising programs and partnerships.

Scientific and technological innovations

• Alloevasion 5.0 platform enables iPSC-derived cells to evade both cellular and humoral immune responses, using unique edits such as a universal NK cell inhibitory ligand and an IgG-degrading protease.

• Preclinical studies show the IgG-degrading protease effectively eliminates antibody-mediated immune attack without systemic IgG depletion.

• iPSC cell foundry allows direct differentiation into various cell types, supporting scalable and reproducible manufacturing.

Strategic focus and future directions

• Emphasis on scalable manufacturing to address large patient populations in autoimmune diseases and type 1 diabetes.

• Ongoing and potential future partnerships with pharma to expand access and leverage Alloevasion technology in new fields.

• Exploring regenerative medicine applications beyond immune cell types, such as dopaminergic neurons for Parkinson’s and heart muscle cells for cardiac disease.